2.1 = | 1.730 Cit. to date |
842 Docs. to date |
Updated monthly
Joana Serôdio, Joana Carneiro, Manuel Veiga, António Ferreira
2019-06-28
Views: 1145
HTML: 126
PDF: 483
|
Olmesartan's sprue-like enteropathy was first described in 2012 and typically presents with diarrhoea, weight loss, nausea, vomiting, low albumin and histological evidence of intestinal villous atrophy. Coeliac disease is one of the main differential diagnoses and should be excluded. We present the clinical case of a 63-year-old man treated with olmesartan for 10 years who presented with a 2-month history of diarrhoea and was diagnosed with olmesartan´s enteropathy. This case highlights the need for clinical suspicion of this new entity in order to reduce the associated morbidity and unnecessary costly investigations.
Ana Rita Matos, Elisabete Coelho, Sofia Caridade
2020-05-15
Views: 1745
HTML: 85
PDF: 430
|
A 77-year-old man with arterial hypertension and dyslipidaemia, treated with olmesartan/hydrochlorothiazide and simvastatin, was admitted with a 3-week history of anorexia, nausea, vomiting, profuse diarrhoea and weight loss. He was dehydrated and blood tests showed acute kidney injury. The aetiological study was inconclusive. The patient had a favourable clinical evolution during hospitalization and was discharged. However, after about 10 days at home, he was re-admitted to hospital with the same clinical presentation. It was noticed that olmesartan had not been prescribed during the previous admission but had been restarted on an outpatient basis. Biopsy examination showed duodenal mucosa with villous atrophy and polymorphic inflammatory infiltrate. Antibody testing for coeliac disease was negative. Based on these facts, it was hypothesized that the patient had olmesartan-induced enteropathy, which was subsequently confirmed.
Mónica Martins Teixeira, Sara Macedo, Ana Sofia Martins, Tânia Batista, António Novais, Maria Costa, Eugénia Maria Cancela
2019-04-12
Views: 1611
HTML: 180
PDF: 615
|
Olmesartan-associated enteropathy is a rare cause of severe enteropathy that should be considered in the differential diagnosis of patients with unexplained chronic diarrhoea. It may be difficult to recognise because of its clinical and histologic similarities to other clinical entities. The authors present the case of a 72-year-old woman with a 6-month clinical history of non-bloody diarrhoea and weight loss. Discontinuation of olmesartan resulted in clinical and histologic recovery, and therefore, physicians need to be aware of olmesartan-associated enteropathy in order to avoid unnecessary testing. Although rare, it is considered an emerging and underdiagnosed enteropathy.
2.1 = | 1.730 Cit. to date |
842 Docs. to date |
Official Journal of the
European Federation of Internal Medicine
www.efim.org
Publisher: SMC media Srl
Via Giovenale, 7 - 20136 Milan - Italy
P.IVA 07626490960
info@ejcrim.com
www.ejcrim.com - ISSN: 2284-2594 - © EFIM 2014-2023, Published by SMC Media srl, Italy - Privacy policy